Institutional members access full text with Ovid®

Share this article on:

An Eastern Cooperative Oncology Group Phase I-II Pilot Study of Polyriboinosinic-Polyribocytidylic Acid Poly-L-lysine Complex in Patients with Metastatic Malignant Melanoma.

Hawkins, Michael J.; Levin, Mark; Borden, Ernest C.
Journal of Biological Response Modifiers: December 1985
Proceedings: Clinical Studies: PDF Only

Summary: Sixteen patients with metastatic malignant melanoma were treated with poly(I,C)-LC 5 mg/m2 twice weekly by intravenous injection. No antitumor responses occurred. Fever (frequently >40[degrees]C) and fatigue were dose limiting toxicities. One patient developed a fever of 42.2[degrees]C when poly(I,C)-LC was given on 2 consecutive days. Interferon was consistently detected in the serum 8 h after a single injection of poly(I,C)-LC (median titer 199 U/ml). No enhancement of interferon induction was detected on the second day when poly(I,C)-LC was given on 2 consecutive days.

(C) Lippincott-Raven Publishers.